ADVA unveils new DCI OLS for the 400ZR era
30.3.2021 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its new FSP 3000 data center interconnect (DCI) open line system (OLS) specifically designed for 400ZR technologies. The new DCI OLS addresses the most urgent challenges for network operators by enabling commercial deployments of DCI infrastructure based on 400ZR. These high-density, cost-effective, open solutions that are optimized for point-to-point applications up to 120km will be key to rapidly expanding DCI capacity to meet soaring data demand. Currently undergoing customer testing and evaluation, the ADVA DCI OLS has demonstrated seamless interoperability with 400ZR pluggable transceivers. The solution is fully compliant and even outperforms the 400ZR standard. What’s more, with data center-compatible open APIs, it can be directly integrated into SDN environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210330005055/en/
ADVA’s new DCI OLS will be pivotal to unlocking the full potential of 400ZR (Photo: Business Wire)
“Today we’re announcing a major milestone for open, high-capacity data center networks. The launch of our new DCI OLS will be key for operators. It provides the missing link to real-world deployments of open infrastructure built with 400ZR interfaces,” said Christoph Glingener, CTO, ADVA. “Our pedigree in the DCI space is second to none. We were the original DCI company, enabling Fortune 500 companies around the globe to harness the cloud with best-in-breed solutions. For more than 25 years, our innovation has helped the industry evolve. Now we’re giving large-scale DCI providers what they need to move forward. Our next-generation FSP 3000 DCI OLS offers a way to inject ultra-high capacity while reducing total cost of ownership and operational complexity. What’s more, the ADVA FSP 3000 DCI OLS solution is designed to optimize performance with 400ZR-compliant optics from any vendor.”
The ADVA FSP 3000 DCI OLS is fully compliant with the OIF’s implementation agreement for 400ZR coherent optical interfaces. Optimized for amplified 400Gbit/s DWDM links with reaches up to 120km at 75GHz or 100GHz channel spacing, the solution exceeds all 400ZR performance specifications. It’s also compatible with OpenZR+ interfaces, which expand the application area to DCI applications with distances far beyond 120km. With its open interfaces, the ADVA DCI OLS ensures seamless integration with third-party transceivers and enables network operators to deploy best-of-breed technology. A high level of functional integration minimizes fiber cabling and provides simplified, automated and rapid turnup for optimal performance. The ADVA FSP 3000 DCI OLS integrates multiple diagnostic tools, including built-in OTDR for the monitoring of all fibers and built-in optical channel monitoring. These automated diagnostic capabilities significantly reduce operating costs and improve repair time.
“Omdia is projecting a significant market take-up for 400ZR pluggable technology. 400ZR has many appealing attributes, including multi-vendor interoperability, appealing cost per bit, and a small form factor with low power consumption. Additionally, 400ZR will be practically deployable in switch/routing platforms, enabling the realization of a decades-long service provider dream,” commented Ian Redpath, practice leader, transport networks and components, Omdia. “ADVA has a proven co-development track record in supporting open and innovative DCI solutions. With its new DCI OLS, ADVA is ideally positioned to take the open line system concept to the next level, interworking directly with 400ZR. And with open API support, ADVA will ensure tight integration with cloud and network provider SDN orchestration and control systems.”
Watch this video for more information on the new DCI OLS: https://youtu.be/8zI3E46oMBo.
Further details are also available in these slides: https://adva.li/dci-ols-400zr-slides.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330005055/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release
Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release
Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 11:00:00 EEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 11:00:00 EEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
